{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:29:16Z","timestamp":1762032556090},"reference-count":18,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The mouse double minute 2 (MDM2) oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumor suppressor protein. Further, MDM2 overexpression can inhibit DNA double-strand break repair in a p53-independent manner. Recently, it was shown that a single nucleotide polymorphism (SNP) in the MDM2 promoter was associated with an accelerated tumor formation in individuals with a p53 mutation. The present case-control study investigated the association of this SNP (IVS1+309) with the risk and the age of onset of familial breast cancer in patients with unknown p53 mutation status. Data from 549 women affected by familial breast cancer and 1,065 healthy controls were analyzed. The cases did not carry BRCA1\/2 mutations. Cases and controls showed a similar genotype distribution and the SNP did not seem to modify the age of onset of familial breast cancer. The data were also examined taking into account the presence of any additional cancer after breast cancer and the family history of cases; however, no association was found. These results suggest that the SNP IVS1+309 alone affects neither the risk nor the age of onset of heritable breast cancer. (Cancer Res 2006; 66(2): 646-8)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-3168","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T20:04:17Z","timestamp":1137701057000},"page":"646-648","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Single Nucleotide Polymorphism IVS1+309 in <i>Mouse Double Minute 2<\/i> Does Not Affect Risk of Familial Breast Cancer"],"prefix":"10.1158","volume":"66","author":[{"given":"Stefan","family":"Wilkening","sequence":"first","affiliation":[{"name":"1Department of Molecular Genetic Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum);"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justo Lorenzo","family":"Bermejo","sequence":"additional","affiliation":[{"name":"1Department of Molecular Genetic Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum);"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Burwinkel","sequence":"additional","affiliation":[{"name":"1Department of Molecular Genetic Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum);"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru\u0308diger","family":"Klaes","sequence":"additional","affiliation":[{"name":"2Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus R.","family":"Bartram","sequence":"additional","affiliation":[{"name":"2Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons","family":"Meindl","sequence":"additional","affiliation":[{"name":"3Department of Gynaecology and Obstetrics, Division for Tumor Genetics, Klinikum rechts der Isar;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bugert","sequence":"additional","affiliation":[{"name":"5Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden-Wu\u0308rttemberg-Hessia, Faculty of Clinical Medicine, University of Heidelberg, Mannheim, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita K.","family":"Schmutzler","sequence":"additional","affiliation":[{"name":"6Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Cologne, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Wappenschmidt","sequence":"additional","affiliation":[{"name":"6Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Cologne, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[{"name":"4Department of Gynaecology and Obstetrics at the Ludwig-Maximilians-University, Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[{"name":"1Department of Molecular Genetic Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum);"},{"name":"7Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asta","family":"Fo\u0308rsti","sequence":"additional","affiliation":[{"name":"1Department of Molecular Genetic Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum);"},{"name":"7Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2006,1,19]]},"reference":[{"key":"2022061622273926700_B1","doi-asserted-by":"crossref","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell\u20081992; 69: 1237\u201345.","DOI":"10.1016\/0092-8674(92)90644-R"},{"key":"2022061622273926700_B2","doi-asserted-by":"crossref","unstructured":"Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol\u20082003; 13: 49\u201358.","DOI":"10.1016\/S1044-579X(02)00099-8"},{"key":"2022061622273926700_B3","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets\u20082005; 5: 9\u201320.","DOI":"10.2174\/1568009053332618"},{"key":"2022061622273926700_B4","doi-asserted-by":"crossref","unstructured":"McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer\u20081995; 71: 981\u20135.","DOI":"10.1038\/bjc.1995.189"},{"key":"2022061622273926700_B5","doi-asserted-by":"crossref","unstructured":"Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer\u20081994; 30A: 982\u20134.","DOI":"10.1016\/0959-8049(94)90128-7"},{"key":"2022061622273926700_B6","doi-asserted-by":"crossref","unstructured":"Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell\u20082004; 119: 591\u2013602.","DOI":"10.1016\/j.cell.2004.11.022"},{"key":"2022061622273926700_B7","doi-asserted-by":"crossref","unstructured":"Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res\u20082005; 65: 5481\u20134.","DOI":"10.1158\/0008-5472.CAN-05-0825"},{"key":"2022061622273926700_B8","doi-asserted-by":"crossref","unstructured":"Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol\u20082003; 25: 190\u2013202.","DOI":"10.1002\/gepi.10261"},{"key":"2022061622273926700_B9","doi-asserted-by":"crossref","unstructured":"Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet\u20082003; 112: 434\u20135.","DOI":"10.1007\/s00439-002-0902-4"},{"key":"2022061622273926700_B10","doi-asserted-by":"crossref","unstructured":"Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene\u20082001; 20: 4621\u20138.","DOI":"10.1038\/sj.onc.1204621"},{"key":"2022061622273926700_B11","doi-asserted-by":"crossref","unstructured":"Meindl A. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer\u20082002; 97: 472\u201380.","DOI":"10.1002\/ijc.1626"},{"key":"2022061622273926700_B12","doi-asserted-by":"crossref","unstructured":"Lorenzo Bermejo J, Hemminki K. A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations. Ann Oncol\u20082005; 16: 322\u20139.","DOI":"10.1093\/annonc\/mdi041"},{"key":"2022061622273926700_B13","doi-asserted-by":"crossref","unstructured":"Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2005. [Epub ahead of print].","DOI":"10.1136\/jmg.2005.037952"},{"key":"2022061622273926700_B14","doi-asserted-by":"crossref","unstructured":"Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2005. [Epub ahead of print].","DOI":"10.1016\/j.canlet.2005.09.003"},{"key":"2022061622273926700_B15","doi-asserted-by":"crossref","unstructured":"Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res\u20082005; 11: 6840\u20134.","DOI":"10.1158\/1078-0432.CCR-05-1139"},{"key":"2022061622273926700_B16","doi-asserted-by":"crossref","unstructured":"Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med\u20082003; 348: 2339\u201347.","DOI":"10.1056\/NEJMra012284"},{"key":"2022061622273926700_B17","doi-asserted-by":"crossref","unstructured":"Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T\u2192G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet\u20082005; 42: 694\u20138.","DOI":"10.1136\/jmg.2005.031260"},{"key":"2022061622273926700_B18","doi-asserted-by":"crossref","unstructured":"Dupont WD, Plummer WD, Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials\u20081998; 19: 589\u2013601.","DOI":"10.1016\/S0197-2456(98)00037-3"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/2\/646\/2554454\/646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/2\/646\/2554454\/646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:37:46Z","timestamp":1655429866000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/2\/646\/526247\/The-Single-Nucleotide-Polymorphism-IVS1-309-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,1,19]]},"published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-3168","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}